

## ONGOING PROJECTS

Title	Acronym	Study period	Financial support	Study Status	Patient included vs. committed
A non interventional study to follow and evaluate patients with advanced non-small cell lung cancer (NSCLC) who are treated in a second line setting with Erlotinib in an "real life" clinical setting.	TEAM	August 2008 - December 2010	Sponsor	Ongoing	8 / 10
Randomized multicentric Phase II study of prolonged adjuvant Temozolomide or "stop and go" in glioblastoma patients.	PATSGO	September 2008 - July 2010	Academic	Ongoing	2 patients included
A non-interventional observational post authorisation safety study of subjects treated with lenalidomide.	PASS	April 2009 - April 2014	Sponsor	In preparation	3-5 per site 2 sites planned
Multicenter, randomized, parallel group efficacy and safety study for the prevention of venous thromboembolism in hospitalized medically ill patients comparing rivaroxaban with enoxaparin.	MAGELLAN	March 2009 - June 2010	Sponsor	Ongoing	5 / 16
An open-label expanded access study of Lapatinib and Capecitabine therapy in subjects with ErbB2 over-expressing locally advanced or metastatic breast cancer.	LAPATINIB	September 2008 - June 2010	Sponsor	End of study	23 included
Biomarker discovery and validation in lung cancer.	IBBL 0001	September 2009 - September 2012	Academic	Ongoing	11 / 150
Prospective evaluation of small molecule EGFR-1 tyrosine kinase inhibition as a first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) harbouring a mutant EGFR gene.	FIELT	January 2009 - November 2010	Academic	Ongoing	10 / 10 screened (1 positive mutation included)
A multinational, multicenter, post-authorization, prospective observational cohort study to assess the profile of vildagliptin and the fixed-dose combination of vildagliptin/metformin relative to comparator oral anti-diabetic drugs in patients with type 2 diabetes in a real-world setting.	EDGE	September 2009 - May 2014	Sponsor	Ongoing	200 planned
Current practice of Aranesp in the management of haemoglobin levels: an observational international cancer evaluation.	CHOICE	September 2009 - June 2010	Sponsor	End of study	4 / 10
A phase III, randomized, double-blind, placebo-controlled multicentre study of ASA404 in combination with docetaxel in second-line treatment of patients with advanced or metastatic (stage IIIb/IV) non-small cell lung cancer (NSCLC).	CASA 404	May 2009 - January 2011	Sponsor	In preparation	10 planned
A randomized double-blind placebo-controlled study to evaluate the long-term safety and efficacy of Darbepoetin Alfa administered at 500 ug once every 3 weeks in anaemic subjects with advanced stage non-small cell lung cancer receiving multi-cycle chemotherapy.	ARANESP 782	January 2010 - January 2017	Sponsor	In preparation	7 patients per site / 2 sites planned
Study of the prevalence and treatment of anaemia ( $\leq 12$ g/dl) in cancer patients treated with chemotherapy and / or radiotherapy or treatment follow-up in the Grand Duchy of Luxemburg.	ANEMIA	June 2009 - June 2010	CRP-Santé via MESR*	Ongoing	57 / 90
Nutrition and physical activity in patients with cerebrovascular disease.	ALVINA	January 2009 - February 2012	CRP-Santé via MESR*	Ongoing	34 / 100
Single center pilot study of the clinical evaluation of the use of <sup>18</sup> FNa in the nuclear medicine department in a 2nd diagnostic intention in orthopedic pathologies.	FNa18	January 2009 - March 2012	CRP-Santé via MESR*	In preparation	50-100 patients planned